Breast Cancer

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved from cancer.

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.

Practicing consistency has made a difference for me while living with stage 4 breast cancer.

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

A revelation has given me perspective for the New Year, inspiring me to embrace change, set new goals and upgrade myself to a better version in 2025.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.

I reflect on my unexpected bond with a neighbor during my breast cancer treatment, finding comfort in his company when I needed someone to talk to.

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

The myth that "healthy people don’t get cancer" contributed to my shame, but I’ve learned that cancer can affect anyone, regardless of lifestyle choices.

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.